reboxetine has been researched along with pindolol in 1 studies
Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (pindolol) | Trials (pindolol) | Recent Studies (post-2010) (pindolol) |
---|---|---|---|---|---|
626 | 193 | 184 | 3,718 | 662 | 92 |
Protein | Taxonomy | reboxetine (IC50) | pindolol (IC50) |
---|---|---|---|
Beta-2 adrenergic receptor | Homo sapiens (human) | 0.0005 | |
Beta-1 adrenergic receptor | Homo sapiens (human) | 0.0009 | |
Beta-3 adrenergic receptor | Homo sapiens (human) | 0.088 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.048 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.048 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fava, M | 1 |
1 review(s) available for reboxetine and pindolol
Article | Year |
---|---|
New approaches to the treatment of refractory depression.
Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Drug Therapy, Combination; Humans; Lithium; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Pindolol; Piperazines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thyroxine; Triazoles; Triiodothyronine | 2000 |